Skip to main
ANIX

ANIX Stock Forecast & Price Target

ANIX Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Anixa Biosciences Inc. is advancing its clinical programs significantly, with the completion of final patient visits in its Phase 1 breast cancer vaccine trial and positive results showing a 74% immune response in participants. The company's proprietary CAR-T technology has strengthened its intellectual property position, providing a competitive edge in the oncology sector. With plans to engage regulators and further develop its neoadjuvant combination designs, Anixa's strategic focus on both preventive and therapeutic solutions positions the company favorably for future growth in immuno-oncology.

Bears say

Anixa Biosciences Inc. continues to face challenges in translating its cancer-focused innovations into viable commercial products, as evidenced by ongoing research and development expenditures that exceed revenue generation. The company's reliance on significant funding to support its pipeline has raised concerns about sustainability, particularly given the high costs associated with developing oncology therapeutics and diagnostics. Furthermore, the competitive landscape in biotechnology presents formidable risks, as numerous other companies are also targeting similar unmet needs in the oncology space, potentially limiting Anixa's market share and growth prospects.

ANIX has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anixa Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anixa Biosciences Inc (ANIX) Forecast

Analysts have given ANIX a Strong Buy based on their latest research and market trends.

According to 3 analysts, ANIX has a Strong Buy consensus rating as of Dec 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anixa Biosciences Inc (ANIX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.